Cat. No：GM-87823AB
Product：Anti-CD276(B7H3)-DXD (Dar4)[Ifinatamab deruxtecan]
Cat. No：GM-87823AB
Product：Anti-CD276(B7H3)-DXD (Dar4)[Ifinatamab deruxtecan]
GM-87823AB-100 / 100μg
GM-87823AB-1mg / 1mg
Expression System | CHO |
Purity | > 95% as determined by SDS-PAGE |
Aggregation | < 5% as determined by SEC-HPLC |
Drug-to-Antibody Ratio (DAR) | 4.0 |
Endotoxin | <1 EU/mg |
Sterility | 0.22 μm Filtered |
Target | B7H3 |
Clone | Ifinatamab deruxtecan |
Alternative Names | 4Ig-B7-H3, B7-H3, CD276, B7RP-2 |
Source/Isotype | Monoclonal Human IgG1, κ |
Application | Positive control of Cytotoxicity Assay |
Description | Ifinatamab deruxtecan is an antibody-drug conjugate (ADC) that combines a specific monoclonal antibody with the potent cytotoxic agent deruxtecan, enabling precise delivery of the drug to a specific target on the surface of tumor cells, thereby effectively killing them. This drug specifically targets B7-H3 (CD276), a protein that is highly expressed in various tumors and has immunosuppressive functions. Due to B7-H3’s tumor-associated expression and its role in regulating immune evasion, it has become an important target for ADC therapy. By targeting B7-H3 and delivering the cytotoxic agent, ifinatamab deruxtecan provides a precise and effective strategy for tumor treatment. |
Formulation | 10 mM NaAc-HAc, pH5.0 |
Cat. No：GM-87823AB
Product：Anti-CD276(B7H3)-DXD (Dar4)[Ifinatamab deruxtecan]
GM-87823AB-100 / 100μg
GM-87823AB-1mg / 1mg
Expression System | CHO |
Purity | > 95% as determined by SDS-PAGE |
Aggregation | < 5% as determined by SEC-HPLC |
Drug-to-Antibody Ratio (DAR) | 4.0 |
Endotoxin | <1 EU/mg |
Sterility | 0.22 μm Filtered |
Target | B7H3 |
Clone | Ifinatamab deruxtecan |
Alternative Names | 4Ig-B7-H3, B7-H3, CD276, B7RP-2 |
Source/Isotype | Monoclonal Human IgG1, κ |
Application | Positive control of Cytotoxicity Assay |
Description | Ifinatamab deruxtecan is an antibody-drug conjugate (ADC) that combines a specific monoclonal antibody with the potent cytotoxic agent deruxtecan, enabling precise delivery of the drug to a specific target on the surface of tumor cells, thereby effectively killing them. This drug specifically targets B7-H3 (CD276), a protein that is highly expressed in various tumors and has immunosuppressive functions. Due to B7-H3’s tumor-associated expression and its role in regulating immune evasion, it has become an important target for ADC therapy. By targeting B7-H3 and delivering the cytotoxic agent, ifinatamab deruxtecan provides a precise and effective strategy for tumor treatment. |
Formulation | 10 mM NaAc-HAc, pH5.0 |
